Douglas G. Altman

957 total papers · 816.0k total citations
656 papers, 614.2k citations indexed

About

Douglas G. Altman is a scholar working on Statistics, Probability and Uncertainty, Economics and Econometrics and Statistics and Probability. According to data from OpenAlex, Douglas G. Altman has authored 656 papers receiving a total of 614.2k indexed citations (citations by other indexed papers that have themselves been cited), including 347 papers in Statistics, Probability and Uncertainty, 183 papers in Economics and Econometrics and 139 papers in Statistics and Probability. Recurrent topics in Douglas G. Altman's work include Meta-analysis and systematic reviews (333 papers), Health Systems, Economic Evaluations, Quality of Life (178 papers) and Statistical Methods in Clinical Trials (101 papers). Douglas G. Altman is often cited by papers focused on Meta-analysis and systematic reviews (333 papers), Health Systems, Economic Evaluations, Quality of Life (178 papers) and Statistical Methods in Clinical Trials (101 papers). Douglas G. Altman collaborates with scholars based in United Kingdom, United States and Canada. Douglas G. Altman's co-authors include David Moher, Jennifer Tetzlaff, Alessandro Liberati, Peter C Gøtzsche, Julian P. T. Higgins, A. Liberati, Jonathan J Deeks, Matthias Egger, Simon G. Thompson and Stuart Pocock and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Douglas G. Altman

646 papers receiving 603.4k citations

Hit Papers

Preferred reporting items... 1983 2026 1997 2011 2009 2009 2003 2009 2009 20.0k 40.0k 60.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
    2009 73.9k citations David Moher, Jennifer Tetzlaff et al. BMJ profile →
  2. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
    2009 51.6k citations David Moher, Alessandro Liberati et al. PLoS Medicine profile →
  3. Measuring inconsistency in meta-analyses
    2003 49.2k citations Julian P. T. Higgins, Simon G. Thompson et al. BMJ profile →
  4. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
    2009 43.1k citations David Moher, Alessandro Liberati et al. PubMed profile →
  5. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
    2009 24.3k citations Alessandro Liberati, Douglas G. Altman et al. PLoS Medicine profile →
  6. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
    2007 17.9k citations Erik von Elm, Douglas G. Altman et al. PLoS Medicine profile →
  7. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
    2009 16.1k citations David Moher, Alessandro Liberati et al. Journal of Clinical Epidemiology profile →
  8. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
    2007 12.3k citations Erik von Elm, Douglas G. Altman et al. Annals of Internal Medicine profile →
  9. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
    2007 11.4k citations Erik von Elm, Douglas G. Altman et al. The Lancet profile →
  10. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
    2010 10.8k citations Kenneth F. Schulz, Douglas G. Altman et al. BMC Medicine profile →
  11. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
    2008 9.8k citations Erik von Elm, Douglas G. Altman et al. Journal of Clinical Epidemiology profile →
  12. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
    2010 9.6k citations David Moher, Alessandro Liberati et al. International Journal of Surgery profile →
  13. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
    2009 8.7k citations Alessandro Liberati, Douglas G. Altman et al. Journal of Clinical Epidemiology profile →
  14. Practical Statistics for Medical Research
    1990 8.5k citations Douglas G. Altman profile →
  15. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
    2009 8.3k citations Alessandro Liberati, Douglas G. Altman et al. Annals of Internal Medicine profile →
  16. Measuring agreement in method comparison studies
    1999 7.2k citations John M. Bland, Douglas G. Altman Statistical Methods in Medical Research profile →
  17. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies
    2014 6.6k citations Erik von Elm, Douglas G. Altman et al. International Journal of Surgery profile →
  18. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide
    2014 6.4k citations Tammy Hoffmann, Paul Glasziou et al. BMJ profile →
  19. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies
    2007 6.1k citations Erik von Elm, Douglas G. Altman et al. BMJ profile →
  20. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
    2007 6.1k citations Jan P. Vandenbroucke, Erik von Elm et al. PLoS Medicine profile →
  21. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
    2015 5.6k citations Brian Hutton, Georgia Salanti et al. Annals of Internal Medicine profile →
  22. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
    2010 5.5k citations Carol Kilkenny, William J. Browne et al. Journal of Pharmacology and Pharmacotherapeutics profile →
  23. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials
    2011 5.5k citations Jonathan A C Sterne, Alex J. Sutton et al. BMJ profile →
  24. Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
    2010 5.4k citations Carol Kilkenny, William J. Browne et al. profile →
  25. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
    2013 4.3k citations An‐Wen Chan, Jennifer Tetzlaff et al. Annals of Internal Medicine profile →
  26. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
    2001 4.2k citations David Moher, Kenneth F. Schulz et al. The Lancet profile →
  27. Practical Statistics for Medical Research.
    1992 4.0k citations Douglas G. Altman et al. profile →
  28. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
    2013 3.5k citations A.-W. Chan, Jennifer Tetzlaff et al. BMJ profile →
  29. Measurement in Medicine: The Analysis of Method Comparison Studies
    1983 3.4k citations Douglas G. Altman, John M. Bland profile →
  30. Chapter 8: Assessing risk of bias in included studies
    2008 3.4k citations Julian P. T. Higgins, Douglas G. Altman profile →
  31. Animal research: Reporting in vivo experiments: The ARRIVE guidelines
    2010 3.2k citations Carol Kilkenny, William J. Browne et al. British Journal of Pharmacology profile →
  32. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
    2015 3.1k citations Karel G.M. Moons, Douglas G. Altman et al. Annals of Internal Medicine profile →
  33. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement
    2015 2.6k citations Gary S. Collins, Johannes B. Reitsma et al. British Journal of Cancer profile →
  34. Interaction revisited: the difference between two estimates
    2003 2.4k citations Douglas G. Altman et al. BMJ profile →
  35. Chapter 9: Analysing Data and Undertaking Meta-Analyses
    2008 2.4k citations Jonathan J Deeks, Julian P. T. Higgins et al. profile →
  36. Evaluating non-randomised intervention studies
    2003 2.3k citations Jonathan J Deeks, Jacqueline Dinnes et al. Health Technology Assessment profile →
  37. Statistical methods for assessing agreement between two methods of clinical measurement
    2010 2.3k citations John M. Bland, Douglas G. Altman International Journal of Nursing Studies profile →
  38. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials
    2001 2.3k citations David Moher, Kenneth F. Schulz et al. BMC Medical Research Methodology profile →
  39. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
    2009 2.3k citations Alessandro Liberati, Douglas G. Altman et al. Italian Journal of Public Health profile →
  40. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement
    2015 2.3k citations Gary S. Collins, Johannes B. Reitsma et al. BMJ profile →
  41. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies
    2015 2.2k citations Patrick M. Bossuyt, Johannes B. Reitsma et al. BMJ profile →
  42. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies
    2007 2.1k citations Erik von Elm, Douglas G. Altman et al. Preventive Medicine profile →
  43. Systematic Reviews in Health Care : Meta-Analysis in Context
    2000 2.0k citations Matthias Egger, Douglas G. Altman et al. profile →
  44. Reprint—Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
    2009 2.0k citations David Moher, Alessandro Liberati et al. profile →
  45. Consort 2010 statement: extension to cluster randomised trials
    2012 2.0k citations Marion Campbell, Gilda Piaggio et al. BMJ profile →
  46. Comparing methods of measurement: why plotting difference against standard method is misleading
    1995 2.0k citations John M. Bland, Douglas G. Altman The Lancet profile →
  47. CONSORT statement: extension to cluster randomised trials
    2004 1.9k citations Marion Campbell, Diana R Elbourne et al. BMJ profile →
  48. Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
    2011 1.9k citations Carol Kilkenny, William J. Browne et al. profile →
  49. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study
    2008 1.8k citations Lesley Wood, Matthias Egger et al. BMJ profile →
  50. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration
    2014 1.8k citations Jan P. Vandenbroucke, Erik von Elm et al. International Journal of Surgery profile →
  51. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
    2007 1.8k citations Jan P. Vandenbroucke, Erik von Elm et al. Epidemiology profile →
  52. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement
    2015 1.8k citations Gary S. Collins, Johannes B. Reitsma et al. Annals of Internal Medicine profile →
  53. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations
    2016 1.8k citations Douglas G. Altman et al. profile →
  54. The cost of dichotomising continuous variables
    2006 1.7k citations Douglas G. Altman, Patrick Royston BMJ profile →
  55. Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration
    2008 1.7k citations Isabelle Boutron, David Moher et al. Annals of Internal Medicine profile →
  56. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
    2005 1.7k citations Lisa M. McShane, Douglas G. Altman et al. JNCI Journal of the National Cancer Institute profile →
  57. Meta-analyses involving cross-over trials: methodological issues
    2002 1.7k citations Diana R Elbourne, Douglas G. Altman et al. International Journal of Epidemiology profile →
  58. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials
    2010 1.7k citations Kenneth F. Schulz, Douglas G. Altman et al. PLoS Medicine profile →
  59. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials
    2011 1.7k citations David Moher, Sally Hopewell et al. International Journal of Surgery profile →
  60. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials
    2010 1.6k citations Kenneth F. Schulz, Douglas G. Altman et al. Journal of Pharmacology and Pharmacotherapeutics profile →
  61. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration
    2016 1.6k citations Jérémie F. Cohen, Daniël A. Korevaar et al. BMJ Open profile →
  62. Dichotomizing continuous predictors in multiple regression: a bad idea
    2005 1.5k citations Patrick Royston, Douglas G. Altman et al. Statistics in Medicine profile →
  63. Statistics Notes: Diagnostic tests 1: sensitivity and specificity
    1994 1.5k citations Douglas G. Altman, J Martin Bland BMJ profile →
  64. Analysing controlled trials with baseline and follow up measurements
    2001 1.5k citations Andrew J. Vickers, Douglas G. Altman BMJ profile →
  65. Confidence intervals rather than P values: estimation rather than hypothesis testing.
    1986 1.5k citations Douglas G. Altman et al. profile →
  66. Agreement Between Methods of Measurement with Multiple Observations Per Individual
    2007 1.4k citations Martin Bland, Douglas G. Altman Journal of Biopharmaceutical Statistics profile →
  67. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
    2010 1.4k citations Kenneth F. Schulz, Douglas G. Altman et al. Trials profile →
  68. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
    2010 1.4k citations David Moher, Sally Hopewell et al. Journal of Clinical Epidemiology profile →
  69. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement
    2007 1.3k citations Erik von Elm, Douglas G. Altman et al. Epidemiology profile →
  70. Statistics Notes: Diagnostic tests 2: predictive values
    1994 1.3k citations Douglas G. Altman, J Martin Bland BMJ profile →
  71. Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist
    2014 1.3k citations Karel G. M. Moons, Joris A. H. de Groot et al. PLoS Medicine profile →
  72. Reporting of Noninferiority and Equivalence Randomized Trials
    2012 1.3k citations Gilda Piaggio, Diana R Elbourne et al. JAMA profile →
  73. Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials
    2004 1.2k citations An‐Wen Chan, Asbjørn Hróbjartsson et al. JAMA profile →
  74. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement
    2015 1.2k citations Gary S. Collins, Johannes B. Reitsma et al. BMC Medicine profile →
  75. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies*
    2007 1.2k citations Erik von Elm, Douglas G. Altman et al. Bulletin of the World Health Organization profile →
  76. Diagnostic tests 4: likelihood ratios
    2004 1.2k citations Jonathan J Deeks, Douglas G. Altman BMJ profile →
  77. No surgical innovation without evaluation: the IDEAL recommendations
    2009 1.2k citations Peter McCulloch, Douglas G. Altman et al. The Lancet profile →
  78. What do we mean by validating a prognostic model?
    2000 1.1k citations Douglas G. Altman, Patrick Royston Statistics in Medicine profile →
  79. Applying the right statistics: analyses of measurement studies
    2003 1.1k citations John M. Bland, Douglas G. Altman Ultrasound in Obstetrics and Gynecology profile →
  80. The COMET Handbook: version 1.0
    2017 1.1k citations Paula Williamson, Douglas G. Altman et al. Trials profile →
  81. The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials
    2001 1.0k citations David Moher, Kenneth F. Schulz et al. Annals of Internal Medicine profile →
  82. REporting recommendations for tumour MARKer prognostic studies (REMARK)
    2005 1.0k citations Lisa M. McShane, Douglas G. Altman et al. British Journal of Cancer profile →
  83. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): Extending the CONSORT Statement
    2010 989 citations Hugh MacPherson, Douglas G. Altman et al. PLoS Medicine profile →
  84. Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research
    2013 979 citations Ewout W. Steyerberg, Karel G.M. Moons et al. PLoS Medicine profile →
  85. Prognosis and prognostic research: what, why, and how?
    2009 931 citations Karel G.M. Moons, Patrick Royston et al. BMJ profile →
  86. Metan: Fixed- and Random-Effects Meta-Analysis
    2008 883 citations Jonathan J Deeks, Douglas G. Altman et al. profile →
  87. Reporting of Noninferiority and Equivalence Randomized Trials
    2006 841 citations Gilda Piaggio, Diana R Elbourne et al. JAMA profile →
  88. Reducing waste from incomplete or unusable reports of biomedical research
    2014 795 citations Paul Glasziou, Douglas G. Altman et al. The Lancet profile →
  89. Guidance for Developers of Health Research Reporting Guidelines
    2010 790 citations David Moher, Kenneth F. Schulz et al. PLoS Medicine profile →
  90. Influence of Reported Study Design Characteristics on Intervention Effect Estimates From Randomized, Controlled Trials
    2012 766 citations Jelena Savović, Douglas G. Altman et al. Annals of Internal Medicine profile →
  91. Confidence intervals for the number needed to treat
    1998 716 citations Douglas G. Altman BMJ profile →
  92. Prognosis and prognostic research: application and impact of prognostic models in clinical practice
    2009 675 citations Karel G.M. Moons, Douglas G. Altman et al. BMJ profile →
  93. Systematic reviews of evaluations of prognostic variables
    2001 633 citations Douglas G. Altman BMJ profile →
  94. Epidemiology and Reporting Characteristics of Systematic Reviews
    2007 626 citations David Moher, Jennifer Tetzlaff et al. PLoS Medicine profile →
  95. The logrank test
    2004 625 citations Martin Bland, Douglas G. Altman BMJ profile →
  96. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review
    2006 624 citations Amy C. Plint, David Moher et al. profile →
  97. Reporting Recommendations for Tumor Marker Prognostic Studies
    2005 613 citations Lisa M. McShane, Douglas G. Altman et al. profile →
  98. External validation of a Cox prognostic model: principles and methods
    2013 595 citations Patrick Royston, Douglas G. Altman BMC Medical Research Methodology profile →
  99. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice
    2002 583 citations Julian P. T. Higgins, Jonathan J Deeks et al. profile →
  100. A note on the use of the intraclass correlation coefficient in the evaluation of agreement between two methods of measurement
    1990 561 citations Martin Bland, Douglas G. Altman Computers in Biology and Medicine profile →
  101. Calculating the number needed to treat for trials where the outcome is time to an event
    1999 531 citations Douglas G. Altman, Per Kragh Andersen BMJ profile →
  102. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
    2012 524 citations Lucy Turner, Larissa Shamseer et al. Cochrane Database of Systematic Reviews profile →
  103. PRISMA for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts
    2013 496 citations Elaine Beller, Paul Glasziou et al. PLoS Medicine profile →
  104. Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
    2014 483 citations Carol Kilkenny, William J. Browne et al. profile →
  105. External validation of multivariable prediction models: a systematic review of methodological conduct and reporting
    2014 481 citations Gary S. Collins, Joris A. H. de Groot et al. BMC Medical Research Methodology profile →
  106. Epidemiology and Reporting Characteristics of Systematic Reviews of Biomedical Research: A Cross-Sectional Study
    2016 474 citations Matthew J. Page, Larissa Shamseer et al. PLoS Medicine profile →
  107. Reporting and Methods in Clinical Prediction Research: A Systematic Review
    2012 451 citations Walter Bouwmeester, Nicolaas P. A. Zuithoff et al. PLoS Medicine profile →
  108. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study
    2015 420 citations Gary S. Collins, Emmanuel Ogundimu et al. Statistics in Medicine profile →
  109. Treatment allocation by minimisation
    2005 402 citations Douglas G. Altman, Martin Bland BMJ profile →
  110. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane reviewa
    2012 399 citations Lucy Turner, Larissa Shamseer et al. Systematic Reviews profile →
  111. Sample size for binary logistic prediction models: Beyond events per variable criteria
    2018 361 citations Maarten van Smeden, Karel G. M. Moons et al. Statistical Methods in Medical Research profile →
  112. Population attributable fraction
    2018 304 citations Mohammad Alì Mansournia, Douglas G. Altman BMJ profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Douglas G. Altman 109.9k 75.0k 73.3k 65.3k 55.4k 656 614.2k
David Moher 87.3k 0.8× 57.0k 0.8× 66.4k 0.9× 47.8k 0.7× 39.3k 0.7× 814 503.0k
Matthias Egger 36.8k 0.3× 32.8k 0.4× 25.1k 0.3× 20.2k 0.3× 18.6k 0.3× 781 211.1k
Peter C Gøtzsche 40.8k 0.4× 25.6k 0.3× 25.6k 0.3× 23.3k 0.4× 19.9k 0.4× 293 202.4k
Jennifer Tetzlaff 50.0k 0.5× 32.1k 0.4× 32.8k 0.4× 28.0k 0.4× 21.9k 0.4× 42 271.9k
Julian P. T. Higgins 34.2k 0.3× 23.7k 0.3× 18.8k 0.3× 22.8k 0.3× 18.6k 0.3× 470 203.4k
Gordon Guyatt 33.5k 0.3× 22.9k 0.3× 24.0k 0.3× 29.5k 0.5× 19.9k 0.4× 1.4k 172.9k
George Davey Smith 23.1k 0.2× 26.4k 0.4× 32.4k 0.4× 14.2k 0.2× 19.3k 0.3× 2.0k 215.4k
Alessandro Liberati 34.4k 0.3× 22.3k 0.3× 23.9k 0.3× 19.1k 0.3× 14.8k 0.3× 87 192.1k
John P. A. Ioannidis 25.8k 0.2× 17.8k 0.2× 20.5k 0.3× 16.0k 0.2× 15.2k 0.3× 1.1k 188.0k
Walter C. Willett 18.9k 0.2× 20.8k 0.3× 97.8k 1.3× 12.3k 0.2× 16.1k 0.3× 1.9k 254.6k

Countries citing papers authored by Douglas G. Altman

Since Specialization
Citations

This map shows the geographic impact of Douglas G. Altman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas G. Altman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas G. Altman more than expected).

Fields of papers citing papers by Douglas G. Altman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas G. Altman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas G. Altman. The network helps show where Douglas G. Altman may publish in the future.

Co-authorship network of co-authors of Douglas G. Altman

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas G. Altman. A scholar is included among the top collaborators of Douglas G. Altman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas G. Altman. Douglas G. Altman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michel Armand Breakdown of academic impact, for papers by Masayuki Yamamoto Breakdown of academic impact, for papers by Adrian L. Harris Breakdown of academic impact, for papers by Bruce Fischl Breakdown of academic impact, for papers by Naomi J. Halas Breakdown of academic impact, for papers by Marcus E. Raichle Breakdown of academic impact, for papers by Matthias Egger Breakdown of academic impact, for papers by Richard J. Davidson
Rankless by CCL
2026